Cost-Effectiveness of Amphotericin B Deoxycholate Versus Itraconazole for Induction Therapy of Talaromycosis in Human Immunodeficiency Virus–Infected Adults in Vietnam. (5th July 2021)

• Record Type: Journal Article
• Authors: Buchanan, James; Altunkaya, James; Van Kinh, Nguyen; Van Vinh Chau, Nguyen; Trieu Ly, Vo; Thi Thanh Thuy, Pham; Hai Vinh, Vu; Thi Hong Hanh, Doan; Thuy Hang, Nguyen; Phuong Thuy, Tran; van Doorn, Rogier; Thwaites, Guy; Gray, Alastair; Le, Thuy
• Is Part Of: Open forum infectious diseases. Volume 8:Number 7(2021)
• Publication Date: 2021-07-05
• Subjects: amphotericin B -- cost-effectiveness -- HIV -- itraconazole -- talaromycosis; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab357
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Background: Talaromycosis (penicilliosis) is an invasive fungal infection and a major cause of human immunodeficiency virus (HIV)–related deaths in Southeast Asia. Guidelines recommend induction therapy with amphotericin B deoxycholate; however, treatment with itraconazole has fewer toxic effects, is easier to administer, and is less expensive. Our recent randomized controlled trial in Vietnam found that amphotericin B was superior to itraconazole with respect to 6-month mortality. We undertook an economic evaluation alongside this trial to determine whether the more effective treatment is cost-effective. Methods: Resource use, direct and indirect costs, and health and quality-of-life outcomes (measured using quality-adjusted life-years [QALYs]) were evaluated for 405 trial participants from 2012 to 2016. Both a Vietnamese health service and a broader societal costing perspective were considered. Mean costs and QALYs were combined to calculate the within-trial cost-effectiveness of amphotericin vs itraconazole from both perspectives. Results: From a Vietnamese health service perspective, amphotericin increases costs but improves health outcomes compared to itraconazole, at a cost of $3013/QALY gained. The probability that amphotericin is cost-effective at a conventional (World Health Organization CHOICE) threshold of value for money is 46%. From a societal perspective, amphotericin is cost-reducing and improves outcomes compared to itraconazole, and is likely to be a cost-effective strategy at any value for money threshold greater than $0. Conclusions: Our analysis indicates that induction therapy with amphotericin is a cost-effective treatment strategy for HIV-infected adults diagnosed with talaromycosis in Vietnam. These results provide the evidence base for health care providers and policy makers to improve access to and use of amphotericin. Abstract : Compared to itraconazole as induction therapy for talaromycosis, amphotericin leads to more adverse events and is more expensive, but reduces mortality. Here, we show that, from a societal perspective, amphotericin is likely to be cost-effective in HIV-infected adults in Asia.